Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by smush74on Jul 20, 2013 12:44pm
204 Views
Post# 21619775

RE:Raxbury increasing sales force? Good idea and a no brainer to me!

RE:Raxbury increasing sales force? Good idea and a no brainer to me! I would take your comments more seriously if you stuck with DND facts and news, if you wish to go off on a tangent on the US financial sector then go to those company boards and blow off your steam there. This board has been clean of those types of ramblings, if you wouldn't mind lets just stick with DND. Like how there are less than 15 million floating shares available to investors, they have no need for outside financing, market potential with their pipline of products.

Where the company sees itself down the road, will they be buyers of other pharma's etc... Their next earnings report will give us all a better picture of what is in our future. Enjoy the ride, it has taken a while for those who have held this stock since its lows or those who were fortunate to buy in at last years prices.
Bullboard Posts